OncoMatch/Clinical Trials/NCT06510283
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
Is NCT06510283 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Taitacept for anti-n-methyl-d-aspartate receptor encephalitis.
Treatment: Taitacept — The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis. Through this prospective, single-center, open-label clinical trial, we aim to investigate the effectiveness and safety of Telitacicept in refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis by add-on therapy of Telitacicept combined with traditional treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: GRIN1 anti-NMDAR (GluN1) IgG antibody detected in CSF
Positive anti-NMDAR (GluN1) IgG antibody detected in CSF
Required: LGI1 antibody detected in serum and/or CSF
positive serum and/or cerebrospinal fluid LGI1 antibody
Demographics
Prior therapy
Must have received: steroids and rituximab or other immunosuppressants (steroids, rituximab, azathioprine, mycophenolate mofetil, cyclophosphamide)
Refractory AE: ineffective treatment with steroids and rituximab or other immunosuppressants, post-treatment mRS score≥2 (stable for at least 24 hours); Recurrent AE: at least 2 months after 1st or 2nd line treatment, new symptoms or worsening of existing symptoms (mRS increase>1)
Cannot have received: biological therapies (rituximab)
Received rituximab or other biological therapies within 1 month prior to enrollment
Lab requirements
Blood counts
white blood cell count<3×10^9 /l, neutrophil count<1.5×10^9 /l, hemoglobin<85g/l, blood platelet count<80×10^9 /l
Kidney function
serum creatinine>1.5×uln
Liver function
tbil(total bilirubin) >1.5×uln, alt>3× uln, ast>3× uln, alkaline phosphatase>2× uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06510283 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior biological therapies disqualifies patients from enrollment.
Does this trial require GRIN1?
Yes, GRIN1 anti-NMDAR (GluN1) IgG antibody detected in CSF is a required biomarker for enrollment.
Does this trial require LGI1?
Yes, LGI1 antibody detected in serum and/or CSF is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify